IMMXImmix Biopharma Inc. Common Stock

13.66USD+3.56%Mkt Cap: 972.45M $P/E:

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Aus…

HeadlineSourceTime
Older
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

Investor's Business Daily
Zacks
Simply Wall St.
Zacks